乳腺癌治疗内分泌耐药机制.pptx
文本预览下载声明
乳腺癌内分泌治疗耐药机制 及临床应对;临床医师面临的内分泌治疗耐药的挑战;;1、早期乳腺癌（M0）内分泌治疗后十年进展率超过三分之一;随访年限;;内分泌治疗可能耐药机制;ER signaling and cross talk with RTKs;Anti-Estrogen therapy leads to RTKs activation;;临床对策概括（一）;临床对策概括（二）;;（1）PI3K inhibitors ;（2）AKT inhibitors;（3）mTOR inhibitors;（4）Dual PI3K-mTOR inhibitors;多个适应症; ;;;;a;总结;
显示全部